Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Study of MEDI-546 in Systemic Lupus Erythematosus
2011-004296-36Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing MEDI-546 with Placebo (2 arms). Primary endpoint: Primary efficacy at Week 24 (Day 169). Started Jun 2012; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2011-004296-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004296-36.